PRODIGE 51 - GASTFOX: Phase III randomised trial evaluating FOLFOX with or without DOCETAXEL (TFOX) as 1st line chemotherapy for locally advanced or metastatic oesophago-gastric adenocarcinoma

Authors :: Sylvain Manfredi
Emmanuelle Samalin
Pascal Artru
A. Zaanan
Faiza Khemissa
Y. Molin
François Ghiringhelli
Ph. Rougier
Julien Taieb
C. Louvet
Carole Monterymard
Olivier Romano
P. Bernard
Nabil Baba-Hamed
Samy Louafi
Benoist Chibaudel
Thomas Aparicio
David Tougeron
Pierre Michel
O. Bouche
Source :: Annals of Oncology. 28:v265
Publication Year :: 2017
Publisher :: Elsevier BV, 2017.

Subjects :: Oncology
medicine.medical_specialty
Chemotherapy
business.industry
medicine.medical_treatment
Locally advanced
Hematology
03 medical and health sciences
Gastric adenocarcinoma
0302 clinical medicine
Docetaxel
FOLFOX
Internal medicine
Medicine
030212 general & internal medicine
Line (text file)
business
030217 neurology & neurosurgery
medicine.drug

Full Text Access

Tools